Synergy and Cytation Readers Validated for Agilent MitoXpress and pH-Xtra Assays

June 18, 2019

BioTek is pleased to announce that its Synergy™ H1 and Synergy Neo2 Hybrid Multi-Mode Readers and its Cytation™ 1 and Cytation 5 Cell Imaging Multi-Mode Readers are validated for use with the MitoXpress and pH-Xtra Assays from Agilent Technologies. The assays may be used alone or combined to measure metabolism in live cells. Instructional Applications Bulletins are available for each multi-mode reader detailing the specific parameters for optimized TRF performance with MitoXpress Xtra Oxygen Consumption, MitoXpress Intracellular Oxygen and pH-Xtra Glycolysis products.   

To date, BioTek’s Cytation 1 and Cytation 5 are the only automated imagers approved for Agilent Seahorse XF data normalization; generating reliable cell counts for improved assay reproducibility and more meaningful biological connections between cell seeding conditions and XF data. Cytation instruments combine automated digital microscopy with filter- and monochromator-based reading for a wide variety of quantitative and qualitative measurements in cell-based assays and more. Advanced Synergy Neo2 and basic Synergy H1 Hybrid Multi-Mode Readers offer highly flexible microplate-based detection through combined filter- and monochromator-based reading.

BioTek Instruments, Inc., headquartered in Winooski, VT, USA, is a worldwide leader in the design, manufacture, and distribution of innovative life science instrumentation. Our comprehensive product line includes cell imaging systems, microplate readers, washers, dispensers, automated incubators and stackers. These products enable life science research by providing high performance, cost-effective analysis and quantification of biomolecules, biomolecular interactions and cellular structure and function across diverse applications. BioTek espouses a "Think Possible" approach that sets the tone for fresh ideas, unsurpassed customer service and original innovations.

For additional information, contact:

Chere Griffin
Expression Marcom, LLC